CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BNPM1EXON 11 MUTATIONPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaDaunorubicinPatel et al., 2012
BNPM1EXON 11 MUTATIONPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaValproic AcidTassara et al., 2014
ENPM1EXON 11 MUTATIONPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaAnti-CD123,Anti-CD33Ehninger et al., 2014
ENPM1EXON 11 MUTATIONPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaAnti-CD33Ehninger et al., 2014
BFLT3MutationPrognosticDoes Not SupportAcute Myeloid LeukemiaFröhling et al., 2004
BFLT3ITDPrognosticDoes Not SupportAcute Myeloid LeukemiaGale et al., 2008
BNPM1EXON 11 MUTATIONPrognosticSupportsBetter OutcomeAcute Myeloid LeukemiaPatel et al., 2012
BNPM1EXON 11 MUTATIONPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaSchnittger et al., 2009
BWT1Exon 7 MutationPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaRenneville et al., 2009
BWT1Exon 7 MutationPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaRenneville et al., 2009
CBCR::ABL1FusionDiagnosticDoes Not SupportPositiveChronic Myeloid LeukemiaSchmidt et al., 2014
BIDH1R132DiagnosticSupportsPositiveAcute Myeloid LeukemiaHo et al., 2010
BKITExon 11 MutationDiagnosticSupportsPositiveGastrointestinal Stromal TumorTaniguchi et al., 1999
BKRASG12CDiagnosticSupportsPositiveLung CancerDogan et al., 2012
BPIK3CAH1047RPredictiveDoes Not SupportResistanceColorectal CancerPanitumumab,CetuximabSartore-Bianchi et al., 2009
DERBB2L755_T759delPredictiveSupportsSensitivity/ResponseBreast CancerNeratinibBose et al., 2013
CFGFR2::OGAFusionPredictiveSupportsSensitivity/ResponseCholangiocarcinomaPonatinibBorad et al., 2014
BIDH1R132PrognosticDoes Not SupportAcute Myeloid LeukemiaWagner et al., 2010
BIDH1R132CPrognosticDoes Not SupportAcute Myeloid LeukemiaAbbas et al., 2010
BIDH2R140PrognosticDoes Not SupportAcute Myeloid LeukemiaZhou et al., 2012
BIDH2R140PrognosticDoes Not SupportMyelodysplastic SyndromeLin et al., 2012
BIDH2R172KPrognosticDoes Not SupportAcute Myeloid LeukemiaZhou et al., 2012
BIDH2R172KPrognosticDoes Not SupportMyelodysplastic SyndromeLin et al., 2012
BKITExon 11 MutationPrognosticDoes Not SupportLung CancerBoldrini et al., 2004
BU2AF1Q157P/RPrognosticDoes Not SupportAcute Myeloid LeukemiaQian et al., 2012
BU2AF1Q157P/RPrognosticDoes Not SupportMyelodysplastic SyndromeQian et al., 2012
BU2AF1S34Y/FPrognosticDoes Not SupportAcute Myeloid LeukemiaQian et al., 2012
BPIK3CAExon 10 MutationPrognosticDoes Not SupportPoor OutcomeColorectal CancerLiao et al., 2012
CPIK3CAH1047RPredictiveSupportsResistanceColorectal CancerPanitumumab,CetuximabSartore-Bianchi et al., 2009
BASXL1MutationPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaOhgami et al., 2015
BABCB1I1145IPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCisplatin,CarboplatinYan et al., 2011
BFGFR1AmplificationPrognosticSupportsBetter OutcomeLung Non-small Cell CarcinomaTran et al., 2013
CKIF5B::RETFusionPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaVandetanibGautschi et al., 2013
DAKT1E17KPredictiveSupportsSensitivity/ResponseMelanomaUprosertibLassen et al., 2014
DPTENLossPredictiveSupportsSensitivity/ResponseMelanomaUprosertibLassen et al., 2014
DPTENLossPredictiveSupportsSensitivity/ResponseBreast CancerPI3Kbeta Inhibitor AZD8186Hancox et al., 2015
BFBXW7MutationPredictiveSupportsResistanceColorectal CancerPanitumumab,CetuximabLupini et al., 2015
BSMAD4MutationPredictiveSupportsResistanceColorectal CancerCetuximab,PanitumumabLupini et al., 2015
CAGK::BRAFFusionPredictiveSupportsSensitivity/ResponseMelanomaSorafenibBotton et al., 2013
DAGK::BRAFFusionPredictiveSupportsResistanceMelanomaVemurafenibBotton et al., 2013
DMYD88OverexpressionPredictiveSupportsResistanceBreast CancerPaclitaxelXiang et al., 2016
DRETOverexpressionPredictiveSupportsSensitivity/ResponseBreast CancerVandetanibHatem et al., 2016
BPTCH1LOHPredictiveSupportsSensitivity/ResponseMedulloblastomaVismodegibRobinson et al., 2015
DSTK11UnderexpressionPredictiveSupportsSensitivity/ResponseProstate CancerSB202190Grossi et al., 2015
CPIK3CAAmplificationPredictiveSupportsSensitivity/ResponseEpithelial Ovarian CancerPictilisibSarker et al., 2015
CBRAFV600EPredictiveSupportsSensitivity/ResponseMelanomaPictilisibSarker et al., 2015
CEML4::ALKFusion AND ALK AmplificationPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinibKim et al., 2013
CEGFRAmplification AND EGFR EGFRVIIIPredictiveSupportsSensitivity/ResponseGlioblastomaAfatinibAlshami et al., 2015
DPTENExpressionPredictiveSupportsSensitivity/ResponseGlioblastomaDacomitinibZahonero et al., 2015
BAREGExpressionPredictiveSupportsResistanceLung Non-small Cell CarcinomaCrizotinibKim et al., 2013
Page 67 of 96
PreviousNext